Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096754 · ClinicalTrials.gov registry record
OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study
A clinical trial of Liver Transplant, sponsored by TransMedics.
- Completed
- Registry status
- 74
- Enrollment target
- 11
- Study locations
NCT05096754: Completed study of Liver Transplant, sponsored by TransMedics.
NCT05096754 is a study of Liver Transplant that has completed, run by TransMedics. The registered enrollment target is 74 participants, below the 5,454-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096754, a study of Liver Transplant, has completed, sponsored by TransMedics.
- COMPLETED
- Registry status
- 74 participants
- Enrollment target
- 11
- Study locations
Study Summary
Post-approval observational study of subjects that were enrolled and transplanted in the OCS Liver PROTECT CAP.
Primary Outcome
Liver Graft Survival at 24 months post-transplant.
Conditions Studied
Interventions
- DEVICE OCS Liver
Study Locations (11)
California
- Scripps - La Jolla
- University of California San Diego - La Jolla
- University of California San Francisco - San Francisco
Texas
- University of Texas Southwest - Dallas
- Houston Methodist Hospital - Houston
- The University of Texas Health Science Center at San Antonio - San Antonio
Maryland
- Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- Mount Sinai - New York
Virginia
- Virginia Commonwealth University Health System - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2023-02-02 |
What the finished NCT05096754 record still lists
NCT05096754 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 5,454-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 1 intervention - of which OCS Liver is the first listed.
NCT05096754 lists 11 locations in 7 states (California, Texas, Maryland).
Frequently Asked Questions
What is clinical trial NCT05096754 about?
NCT05096754 is a clinical study titled "OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study". Post-approval observational study of subjects that were enrolled and transplanted in the OCS Liver PROTECT CAP.
What is the current status of trial NCT05096754?
This trial is currently completed. The enrollment target is 74 participants. The study started on 2020-02-03. Estimated completion is 2023-02-02.
What conditions does trial NCT05096754 study?
This clinical trial studies the following conditions: Liver Transplant.
What interventions are being tested in trial NCT05096754?
The interventions under investigation include: OCS Liver (DEVICE).
Who is sponsoring clinical trial NCT05096754?
This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05096754 being conducted?
This trial has 11 study locations across California, Maryland, Massachusetts, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05096754's enrollment target sits among peer trials
74 10th of 19 higher than 9 of 19 other Liver Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
RECRUITING · Phase 2
-
US National OCS Liver Perfusion (OLP) Registry
RECRUITING
-
Liver Transplant CGM
RECRUITING
-
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
RECRUITING · NA
-
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
RECRUITING · Phase 2
-
EVR and EPO for Liver Transplant Tolerance
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI